In-hospital management and medications at discharge
| Prasugrel | Ticagrelor | P value | |
| Patients, n | 2073 | 35 917 | |
| Percutaneous coronary intervention | |||
| Access site—radial artery | 1359 (65.7) | 28 980 (81.0) | <0.001 |
| Multivessel disease | 1075 (52.1) | 17 669 (49.5) | 0.022 |
| PCI with stent | 1917 (92.7) | 3329 (93.1) | 0.491 |
| Medication before/during PCI* | |||
| Aspirin | 2027 (97.7) | 35 255 (98.2) | 0.165 |
| P2Y12 receptor inhibitor, before PCI | 1871 (90.3) | 31 272 (87.1) | <0.001 |
| Clopidogrel | 1129 (54.5) | 3594 (10.0) | <0.001 |
| Ticagrelor | 159 (7.7) | 27 736 (77.2) | |
| Prasugrel | 632 (30.5) | 339 (0.9) | |
| P2Y12 receptor inhibitor, during PCI | 746 (36.0) | 5457 (15.2) | <0.001 |
| Clopidogrel | 49 (2.4) | 333 (0.9) | <0.001 |
| Ticagrelor | 22 (1.1) | 5255 (14.6) | |
| Prasugrel | 696 (33.6) | 101 (0.3) | |
| P2Y12 receptor inhibitors, before/during PCI | 2045 (98.6) | 35 000 (97.4) | <0.001 |
| Clopidogrel | 360 (27.0) | 1957 (5.4) | <0.001 |
| Ticagrelor | 176 (8.5) | 32 610 (90.8) | |
| Prasugrel | 1309 (63.1) | 433 (1.2) | |
| Unfractionated heparin | 1786 (86.2) | 33 409 (93.0) | <0.001 |
| Glycoprotein IIb/IIIa receptor inhibitor | 154 (7.4) | 2511 (7.0) | 0.448 |
| During the index hospitalisation | |||
| CPAP | 51 (2.5) | 897 (2.5) | 0.914 |
| New-onset AF | 55 (2.7) | 874 (2.4) | 0.531 |
| Intravenous diuretic | 310 (15.0) | 4127 (11.5) | <0.001 |
| Inotropic drug | 105 (5.1) | 917 (2.6) | <0.001 |
| LMWH/fondaparinux | 744 (35.9) | 16 102 (47.1) | <0.001 |
| Medication at discharge | |||
| Aspirin | 2073 (100) | 35 197 (100) | NA |
| Beta blocker | 1908 (92.0) | 32 608 (90.8) | 0.056 |
| ACE-I/ARB | 1844 (89.0) | 30 988 (86.3) | 0.001 |
| Statin | 2024 (97.6) | 35 015 (97.5) | 0.687 |
| Antidiabetic medication | |||
| Oral | 182 (8.8) | 3047 (8.5) | 0.002 |
| Insulin | 225 (10.9) | 3123 (8.7) | |
| Diuretic | 366 (17.7) | 5765 (16.1) | 0.054 |
Results are presented as numbers and percentages unless otherwise indicated.
*Were administrated the last 24 hours before or during PCI.
ACE-I, ACE inhibitor; AF, atrial fibrillation; ARB, angiotensin receptor blocker; CPAP, continuous positive airway pressure; LMWH, low molecular weight heparin; NA, not applicable; PCI, percutaneous coronary intervention.